Propafenone and sotalol: Long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. Double blind placebo-controlled study;Propafenone e sotalolo: Efficacia e tollerabilita a lungo termine nella prevenzione della fibrillazione atriale parossistica. Studio in doppio cieco controllato con placebo

Giornale Italiano di Cardiologia

Volumn 26, Issue 4, 1996, Pages 379-390

  Bellandi, Francesco ^a,c   Dabizzi, Roberto Piero ^b   Niccoli, Laura ^a   Cantini, Fabrizio ^a   Palchetti, Roberto ^a  

^a Ospedale di Prato   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c NONE   (Italy)

Author keywords

atrial fibrillation; propafenone; sotalol

Indexed keywords

PLACEBO; PROPAFENONE; SOTALOL;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROPAFENONE; SOTALOL; TIME FACTORS;

EID: 0030456853     PISSN: 00465968     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM: Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-1022.
2. Kopecky SL, Gersh BJ, McGoon MD et al: The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317: 669-674.
3. Petersen P, Boysen G, Godfredsen J, Andersen ED, Andersen B: Placebo-controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989; 1: 175-179.
4. Chesebro JH, Fuster V, Halperin JL: Atrial fibrillation. Risk marker for stroke. N Engl J Med 1990; 323: 1556-1558.
5. Stroke Prevention in Atrial Fibrillation Investigators: Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-539.
6. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
7. Bazett HC: An analysis of the time-relation of electrocardiograms. Heart 1920; 7: 353-370.
8. Wyatt HL, Meerbaum S, Heng MK, Gueret P, Corday E: Cross-sectional echocardiography, III: analysis of mathematic models for quantifying volume of symmetric and asymmetric left ventricles. Am Heart J 1980; 100: 821-828.
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Petersen P, Godfredsen J: Atrial fibrillation: a review of course and prognosis. Acta Med Scand 1984; 216: 5-9.
11. Gajewsky J, Singer RB: Mortality in an insured population with atrial fibrillation. JAMA 1981; 245: 1540-1548.
12. Brandt FN, Abbott RD, Kannel WB, Wolf PA: Characteristics and prognosis of lone atrial fibrillation, 30 years follow-up in the Framingham study. JAMA 1985; 254: 3449-3452.
13. Capucci A, Boriani G: La fibrillazione atriale e rischio tromboembolico. In: Capucci A (ed): La fibrillazione atriale. Problemi clinici e terapeutici. Milano, Mc Graw-Hill Libri Italia, 1991: 36-41.
14. CAST Investigators Preliminary Report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
15. Hartel G, Louhija A, Koottinen A, Holonen PI: Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. Br Heart J 1970; 32: 57-60.
16. Byrne-Quinn E, Wing AJ: Maintenance of sinus rhythm after DC shock reversion of atrial fibrillation. Br Heart J 1970; 32: 370-376.
17. Gunning JF, Kristinsson A, Miller G, Saunders K: Long-term follow-up of direct current cardioversion after cardiac surgery with special reference to quinidine. Br Heart J 1970; 32: 462-466.
18. Waris E, Kreus KE, Salokanel J: Factors influencing persistence of sinus rhythm after DC shock treatment of atrial fibrillation. Acta Med Scand 1971; 189: 161-166.
19. Resnekov L, Gibson D, Waich S, Muir J, Mcdonald L: Sustained release quinidine (Kinidin Durules) in maintaining sinus rhythm after electroconversion of atrial dysrhythmias. Br Heart J 1971; 33: 220-225.
20. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82: 1106-1116.
21. Hammil SC, Wood DL, Gersh BJ, Osborn MJ, Holmes DR: Propafenone for paroxysmal atrial fibrillation. Am J Cardiol 1988; 61: 473-474.
22. Connolly SJ, Hoffert DL: Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989; 63: 817-819.
23. Bellandi F, Cantini F, Pedone T, Dabizzi RP, Palchetti R: Effectiveness of intravenous propafenone and amiodarone for conversion of recent onset atrial fibrillation. One-year follow-up with oral treatment. G Ital Cardiol 1993; 23: 261-271.
24. Reimold SC, Cantillon CO, Friedman PL, Antman EM: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558-563.
25. Rasmussen K, Andersen A, Abrahamsen AM, Overskeid K, Bathen J: Flecainide versus disopyramide in maintaining sinus rhythm following conversion of chronic atrial fibrillation (Abstract). Eur Heart J 1988; 9 (Suppl 1): 52.
26. Van Gelder I, Crijns H, van Gilst W, Lie KI: Efficacy of flecainide to maintain sinus rhythm after cardioversion of atrial fibrillation and flutter (Abstract). Eur Heart J 1988; 9 (Suppl 1): 52.
27. Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos Santos P: Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol 1992; 70: 44A-49A.
28. Schlepper M: Propafenone, a review of its profile. Eur Heart J 1987; 8 (Suppl A): 27-32.
29. Wang J, Bourne GW, Wang Z, Villemaire C, Talajic M, Nattel S: Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. Circulation 1993; 88: 1030-1044.
30. Capucci A, Gubelli S, Carini G, Fabretti L, Magnani B: Pharmacologic cardioversion with propafenone of stable atrial fibrillation of recent onset. G Ital Cardiol 1987; 17: 975-982.
31. Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M: Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989; 64: 335-338.
32. Hamill SC, McLaran CJ, Wood DL, Osborn MJ, Gersh BJ, Holmes DR: Double-blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. J Am Coll Cardiol 1987; 9: 1364-1368.
33. Waleffe A, Nzayinambaho K, Rodriguez LM, Dehareng A, Kulbertus HE: Mechanisms of termination of supraventricular tachycardias by intravenous class III antiarrhythmic agents. A comparison of amiodarone and sotalol. Eur Heart J 1989; 10: 1084-1089.
34. Mitchell LB, Wyse DG, Duff HJ: Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987; 76: 810-818.
35. Bertrix L, Timour-Chah Q, Lang J, Lakhal M, Fucon G: Protection against ventricular and atrial fibrillation by sotalol. Cardiovasc Res 1986; 20: 358-363.
36. Singh S, Saini RK, DiMarco J et al: Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. Am J Cardiol 1991; 68: 1227-1230.
37. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL: Therapy of refractory symptomatic atrial fibrillation and flutter: a care staged approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15: 698-707.
38. Juul-Moller S, Edvardsson N, Ahlberg NR: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82: 1932-1939.
39. Singh BN: Antiarrhythmic action of DL sotalol in ventricular and supraventricular arrhythmias. J Cardiovasc Pharmacol 1992; 20 (Suppl 2): S75-S90.
40. Warris E, Kreus KE, Salokannel J: Factors influencing persistence of sinus rhythm after dc shock treatment of atrial fibrillation. Acta Med Scand 1971; 189: 161-166.
41. Ewy GA, Ulfers L, Hager WD, Rosenfeld AR, Roeske WR, Goldman S: Response of atrial fibrillation to therapy: role of etiology and left atrial diameter. J Electrocardiol 1980; 13: 119-124.
42. Brodsky MA, Allen BJ, Walker CJ 3d, Casey TP, Luckett CR, Henry WL: Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60: 572-575.
43. Kuch KH, Kunze KP, Roewer N, Bleifeld W: Sotalol-induced torsade de pointes. Am Heart J 1984; 107: 179-180.
44. Soyka LF, Wirtz C, Spangenberg RB: Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990; 65: 74A-81A.